A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis

A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis

<p>Abstract</p> <p>Objective</p> <p>We conducted a single-centre, randomised, double-blinded, placebo-controlled phase II clinical study to test safety and efficacy of a 12-week therapy with low-dose (700 mg/daily) or high-dose (2800 mg/daily) of NAC.</p> <p>...

Full description

Bibliographic Details
Main Authors: Dauletbaev N, Fischer P, Aulbach B, Gross J, Kusche W, Thyroff-Friesinger U, Wagner TOF, Bargon J
Format: Article
Language:English
Published: BMC 2009-08-01
Series:European Journal of Medical Research
Subjects:
Cystic fibrosis
N-acetylcysteine
induced sputum
glutathione
inflammation
Online Access:http://www.eurjmedres.com/content/14/8/352

Internet

http://www.eurjmedres.com/content/14/8/352

Similar Items